Research and Development news

Here you find the latest news on our research and development activities.
Seite: 1 2 3 1-20 von 56 Dokumente

04/04/14, Research and Development Bayer to Present New Data on Advancing Oncology Portfolio New Preclinical and Early Clinical Data Evaluating Innovative Compounds in Drug Development more


02/10/14, Research and Development Two-Year Results From Phase III Trial of VEGF Trap-Eye (aflibercept solution for injection) for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision more


02/04/14, Research and Development Bayer and German Cancer Research Center (DKFZ) in Strategic Alliance Against Cancer Partners extend existing alliance to develop novel cancer therapies / Joint investment of up to 30 million Euros for collaborative research in oncology over the next five years more


01/13/14, Research and Development Bayer and Regeneron to Develop New Treatment Option for Wet Age-Related Macular Degeneration Joint development of Regeneron’s PDGFR Beta antibody as new candidate for potential combination therapy demonstrates both companies’ strong commitment to ophthalmology / Bayer obtains exclusive commercialization rights outside the U.S., where Bayer and Regeneron will share profits / Regeneron retains full U.S. commercialization rights more


01/08/14, Research and Development Bayer and Peking University Establish New Research Center for Translational Research and Drug Discovery in Beijing Bayer HealthCare and Peking University sign collaboration agreement, Research collaboration demonstrates Bayer’s commitment to China as an important location in its innovation strategy more


12/18/13, Research and Development Bayer HealthCare to Join Not-For-Profit Structural Genomics Consortium to Accelerate Research in Epigenetics more


12/05/13, Research and Development Phase II Data of Bayer’s Novel Cancer Drug Candidate Copanlisib to be Presented First Oral Presentation on Preliminary Phase II Data of Copanlisib (BAY 80-6946) in Patients with Indolent or Aggressive Non-Hodgkin’s Lymphoma more


11/22/13, Research and Development Nexavar® Receives Approval for the Treatment of Differentiated Thyroid Cancer in the U.S. First and only FDA-approved treatment option for patients with this type of thyroid cancer / FDA approval based on data from Phase III DECISION trial, in which sorafenib significantly extended progression-free survival compared to placebo more


11/18/13, Research and Development Bayer HealthCare, Inception Sciences and Versant Ventures Join Forces to Develop Innovative Therapeutics for Retinal Eye Diseases more


10/09/13, Research and Development Bayer HealthCare to Collaborate with Sysmex Inostics GmbH to Develop Blood-based Companion Diagnostic Tests in Oncology more


10/08/13, Research and Development Bayer Accelerates Clinical Development of Promising New Drug Candidates Five new molecular entities projected to enter Phase III by 2015 / Addressing unmet medical needs in the areas of oncology, cardiology, and women’s health / Initiation of further studies with recently launched products planned to add new treatment options more


09/10/13, Research and Development Bayer and the Broad Institute Join Forces to Develop Novel Treatment Options in Cancer Therapy Collaboration aims at the discovery of innovative cancer therapeutics combining the learnings from cancer genome analysis with novel screening approaches and chemistry more


09/03/13, Research and Development Bayer Partners with Thrombosis Research Institute in a Major Global Registry to Drive Improved Outcomes in Patients Suffering from Deep Vein Thrombosis or Pulmonary Embolism Venous blood clots in the deep veins (DVT) or lungs (PE) remain a medical emergency, killing one person every 37 seconds in the Western World / GARFIELD VTE Registry will study the acute and long-term management of patients suffering from venous blood clots with both traditional dual drug approaches and novel anticoagulants, including the single-drug solution Xarelto® (rivaroxaban) / Led by the Thrombosis Research Institute (TRI), GARFIELD VTE is an independent Registry supported by an unrestricted educational grant from Bayer HealthCare and is designed to help inform payors, policy makers and prescribers on how to improve safety, outcomes and utilisation of healthcare resources / Bayer HealthCare’s Xarelto is the only novel oral anticoagulant approved for the treatment of DVT and PE and the subsequent prevention of recurrence more


08/05/13, Research and Development Bayer Enters Into New Cancer Immunotherapy Collaboration with Compugen Partners have signed collaboration and licence agreement more


07/26/13, Research and Development Bayer Receives Recommendation for Approval of VEGF Trap-Eye (aflibercept solution for injection) for the Treatment of Visual Impairment due to Macular Edema Secondary to Central Retinal Vein Occlusion in Europe more


07/17/13, Research and Development Bayer announces that the New England Journal of Medicine Publishes Results of Phase III ALSYMPCA Study of Radium 223 Dichloride Significant overall survival benefit observed with radium 223 in patients who received prior treatment with docetaxel and in those who did not / Radium 223 significantly delayed time to first symptomatic skeletal event / All main secondary efficacy endpoints with radium 223 were met, showing clinical benefit with radium 223 in patients with castration-resistant prostate cancer and symptomatic bone metastases more


06/25/13, Research and Development Bayer Enters Into New Collaboration with Seattle Genetics for the Development of Anticancer Drugs Bayer will get worldwide rights to utilize Seattle Genetics’ auristatin-based ADC technology / Collaboration strengthens Bayer portfolio in the area of personalized medicine more


05/15/13, Research and Development Bayer Initiates Phase III Trial of Regorafenib in Patients with Advanced Liver Cancer more


04/10/13, Research and Development Bayer HealthCare to broaden strategic alliance with German Cancer Research Center Joint immunotherapy research laboratory at the National Center for Tumor Diseases (NCT) in Heidelberg / Operations at the joint laboratory scheduled to start in the middle of 2013 / Additional investments of up to €3 million per year more


04/08/13, Research and Development U.S. FDA Grants Priority Review to Bayer’s Riociguat for the Treatment of two Life-Threatening Pulmonary Hypertension Indications more

Seite: 1 2 3 1-20 von 56 Dokumente

Research and Development

More information about the topic Research and Development:

Contact Research Form

Page tools
.
Interactive tool
Grants for Targets
Annual Report 2013
Clinical Trials

open
close
http://www.bayerpharma.com/en/research-and-development/news/index.php

Copyright © Bayer Pharma AG